Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Cash (2016 - 2025)

Historic Change in Cash for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $11.8 million.

  • Fortress Biotech's Change in Cash rose 16820.38% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 29178.54%. This contributed to the annual value of -$24.5 million for FY2024, which is 7484.35% up from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Change in Cash is $11.8 million, which was up 16820.38% from -$17.0 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Change in Cash high stood at $56.5 million for Q1 2021, and its period low was -$65.7 million during Q2 2023.
  • Its 5-year average for Change in Cash is -$7.8 million, with a median of -$14.9 million in 2021.
  • Over the last 5 years, Fortress Biotech's Change in Cash had its largest YoY gain of 627989.07% in 2021, and its largest YoY loss of 21035.08% in 2021.
  • Fortress Biotech's Change in Cash (Quarter) stood at $53.6 million in 2021, then plummeted by 155.26% to -$29.6 million in 2022, then skyrocketed by 129.1% to $8.6 million in 2023, then tumbled by 124.37% to -$2.1 million in 2024, then soared by 663.16% to $11.8 million in 2025.
  • Its Change in Cash stands at $11.8 million for Q3 2025, versus -$17.0 million for Q2 2025 and $33.7 million for Q1 2025.